Skip to main content
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Main navigation - Mobile
Sales and Marketing
Special Report—The top 10 cardiovascular drugs in the world
2018 payer talks key to Dupixent's long-term uptake: analyst
Friday, July 14, 2017
Payer hurdles are hampering Dupixent's path to patients' hands, despite early negotiations that yielded upfront coverage.
Cost watchdog pitches lower price for Amgen's Repatha
Wednesday, June 14, 2017
A controversial cost watchdog is going even further on its claim that Amgen's PCSK9 cholesterol med Repatha isn't worth its current cost.
15. Robert Bradway
4. Leonard “Len” Schleifer
Sanofi's Praluent smacks LDL in high-risk diabetics
Sunday, June 11, 2017
Sanofi and Regeneron, battling Amgen in the PCSK9 field, boast new data suggesting Praluent can safely cut "bad" cholesterol in high-risk diabetes patients.
Amgen or Sanofi: Who's got the PCSK9 patent edge now?
Wednesday, June 7, 2017
Who's got the edge in the hot PCSK9 case after court arguments? Amgen has an 80% shot, one analyst said. Nope, Regeneron and Sanofi, says another.
Dupixent's zippy rollout lights a fuse under sales forecasts
Monday, May 8, 2017
Sanofi and Regeneron's eczema med Dupixent has stormed out of the launch gate, prompting analysts to hike their sales estimates for 2017 to as much as $320 million.
Amgen puts Repatha data to work in new refund deal
Wednesday, May 3, 2017
On the heels of highly anticipated cardiovascular outcomes data for PCSK9 med Repatha, Amgen has signed a money-back guarantee with Harvard Pilgrim.
Sanofi enjoys solid Q1, despite continuing erosion of U.S. Lantus sales
Friday, April 28, 2017
Sanofi CEO Olivier Brandicourt has been criticized for failing to pull off a couple of big acquisitions, but his more mundane deal to get Boehringer Ingelheim’s consumer health business helped it turn in a surprisingly strong Q1.